Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors - NIB cohort study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53128

Enrollment

1500

Registered

2008-12-18

Start date

2009-06-18

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer malignancies

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients using a (currently approved or new) targeted anti-cancer agent for treatment of cancer Patients from whom it is possible to collect blood samples Informed consent is given

Exclusion criteria

Exclusion criteria: nvt

Design outcomes

Primary

Measure	Time frame
•Pharmacokinetics	—

Secondary

Measure	Time frame
•Treatment outcome (response, suboptimal response, treatment failure) •Toxicity (graded on basis of the National Cancer Institute Common Toxicity Terminology grading Criteria for adverse events (CTCAE) •Genotype of drug metabolising enzymes and drug transporters •Mutations and/or alterations in drug targets •Drug-drug interactions	—

Countries

Netherlands

Outcome results